Adalimumab monotherapy and combination with methotrexate showed similar drug survival and PASI75 response rates in plaque psoriasis patients. Methotrexate reduced antidrug antibody levels but did not ...
In people with psoriasis taking adalimumab, there was no significant difference between adalimumab monotherapy and adalimumab with concomitant methotrexate, according to a recent report in JAMA ...
Both upadacitinib (Rinvoq) and adalimumab (Humira) are proven effective in rheumatoid arthritis (RA) and psoriatic arthritis ...
AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...
Discontinuing adalimumab increases relapse rates in patients with juvenile idiopathic arthritis (JIA)–associated uveitis. However, patients can regain inflammation control after resuming the treatment ...